- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04452838
Study To Assess The Bioequivalence Under Fed And Fasted Conditions Of The Fesoterodine Beads-In-Capsule SR4 And SR7 Formulations And To Estimate The Bioavailability of SR7 Beads Sprinkled On Apple Sauce Relative To The Beads-In-Capsule SR7 Formulation Administer
February 8, 2021 updated by: Pfizer
A PHASE 1, OPEN-LABEL, SINGLE-DOSE, CROSSOVER STUDY TO ASSESS THE BIOEQUIVALENCE UNDER FED AND FASTED CONDITIONS OF FESOTERODINE BEADS-IN-CAPSULE SR7 AND SR4 FORMULATIONS, THE EFFECT OF FOOD ON THE PHARMACOKINETICS OF THE BEADS-IN-CAPSULE SR7 FORMULATION AND TO ESTIMATE THE BIOAVAILABILITY OF SR7 BEADS SPRINKLED ON APPLE SAUCE RELATIVE TO THE BEADS-IN-CAPSULE SR7 FORMULATION ADMINISTERED INTACT
Open Label, Single-Dose, Crossover Study To Assess The Bioequivalence Under Fed And Fasted Conditions Of The Fesoterodine Beads-In-Capsule (BIC) SR4 And SR7 Formulations And To Estimate The Bioavailability of SR7 Beads Sprinkled On Apple Sauce Relative To The Beads-In-Capsule SR7 Formulation Administered Intact.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
- Drug: Fesoterodine BIC SR4 fasted (Treatment A in Part A, Treatment G in Part B)
- Drug: Fesoterodine BIC SR7 fasted (Treatment B in Part A, Treatment H in Part B)
- Drug: Fesoterodine BIC SR7 fed (Treatment C in Part A, Treatment F in Part B)
- Drug: Fesoterodine BIC SR7 on apple sauce (Treatment D in Part A)
- Drug: Fesoterodine BIC SR4 fed (Treatment E in Part B)
Detailed Description
After oral administration, fesoterodine is not detected in plasma as it is rapidly and extensively hydrolyzed by non-specific esterases to its primary active metabolite 5-hydroxymethyl tolterodine (5-HMT) .
Therefore characterization of the rate and extent of absorption of the test and reference fesoterodine formulations will be based on pharmacokinetic parameters of 5-HMT derived from the 5-HMT concentration-time profiles.
Study Type
Interventional
Enrollment (Actual)
37
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Bruxelles-capitale, Région DE
-
Brussels, Bruxelles-capitale, Région DE, Belgium, B-1070
- Brussels Clinical Research Unit
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria
- Male and female participants must be 18 to 55 years of age, inclusive, at the time of signing the informed consent document (ICD).
- Male and female participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, and laboratory tests.
- Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures. Weight:
- Body mass index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lb).
- Capable of giving signed informed consent
Exclusion Criteria:
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
- Any condition possibly affecting drug absorption (eg, gastrectomy, cholecystectomy).
- History of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C; positive testing for HIV, hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb) or hepatitis C antibody (HCVAb). A positive serology for hepatitis B surface antibody (HBsAb) as a result of Hepatitis B vaccination is allowed.
- Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study.
- History of allergy or hypersensitivity to fesoterodine fumarate or tolterodine tartrate, soya, or any of the excipients in the investigational drug product.
- History of uncontrolled narrow angle glaucoma, myasthenia gravis, gastric retention, severe ulcerative colitis and toxic megacolon.
- Evidence or history of clinically significant urologic disease: urinary retention, obstructive disturbance of bladder emptying, micturition disturbance, nocturia or pollakiuria (eg, benign prostate hyperplasia, urethral stricture, recurrent urinary tract infections).
- Use of prescription or nonprescription drugs and dietary and herbal supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of investigational product.
- Previous administration with an investigational drug within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of investigational product used in this study (whichever is longer).
- A positive urine drug test, as confirmed by a single repeat.
- Screening supine blood pressure (BP) greater than or equal to 140 mm Hg (systolic) or greater than or equal to 90 mm Hg (diastolic), following at least 5 minutes of supine rest. If BP is greater than or equal to 140 mm Hg (systolic) or greater than or equal to 90 mm Hg (diastolic), the BP should be repeated 2 more times and the average of the 3 BP values should be used to determine the participant's eligibility.
- Screening 12-lead electrocardiogram (ECG) that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results (eg, baseline corrected QT (QTc) interval >450 msec, complete left bundle branch block [LBBB], signs of an acute or indeterminate-age myocardial infarction, ST-T interval changes suggestive of myocardial ischemia, second- or third-degree atrioventricular [AV] block, or serious bradyarrhythmias or tachyarrhythmias). If the baseline uncorrected QT interval is greater than 450 msec, this interval should be rate-corrected using the Fridericia method and the resulting corrected QT (QTcF) should be used for decision making and reporting. If QTc exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated 2 more times and the average of the 3 QTc or QRS values should be used to determine the participant's eligibility. Computer-interpreted ECGs should be overread by a physician experienced in reading ECGs before excluding participants.
- Participants with ANY of the following abnormalities in clinical laboratory tests at Screening, as assessed by the study-specific laboratory and confirmed by a single repeat test, if deemed necessary:
- Screening estimated glomerular filtration rate (eGFR) is less than or equal to 90 mL /min/1.73 m2 for Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula).
- History of alcohol abuse or binge drinking and/or any other illicit drug use or dependence within 6 months of Screening. Binge drinking is defined as a pattern of 5 (male) and 4 (female) or more alcoholic drinks in about 2 hours. As a general rule, alcohol intake should not exceed 14 units per week (1 unit = 8 ounces (240 mL) beer, 1 ounce (30 mL) of 40% spirit or 3 ounces (90 mL) of wine).
- Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 60 days prior to dosing.
- Unwilling or unable to comply with the criteria in the Lifestyle Considerations section of this protocol.
- Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or Pfizer employees, including their family members, directly involved in the conduct of the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: Cohort 1 Sequence 1 (Part A)
Treatment Sequence A,B,C and D
|
4 mg administered under fasted condition.
4 mg administered under fasted conditions.
4 mg administered under fed conditions.
4 mg sprinkled on apple sauce administered under fasting conditions
|
OTHER: Cohort 1 Sequence 2 (Part A)
Treatment Sequence B, A,C and D
|
4 mg administered under fasted condition.
4 mg administered under fasted conditions.
4 mg administered under fed conditions.
4 mg sprinkled on apple sauce administered under fasting conditions
|
OTHER: Cohort 2 Sequence 1 (Part B)
Treatment Sequence E, F, G, and H
|
4 mg administered under fasted condition.
4 mg administered under fasted conditions.
4 mg administered under fed conditions.
4 mg administered under fed conditions
|
OTHER: Cohort 2 Sequence 2 (Part B)
Treatment Sequence E, F, H and G
|
4 mg administered under fasted condition.
4 mg administered under fasted conditions.
4 mg administered under fed conditions.
4 mg administered under fed conditions
|
OTHER: Cohort 2 Sequence 3 (Part B)
Treatment Sequence F, E, G, and H
|
4 mg administered under fasted condition.
4 mg administered under fasted conditions.
4 mg administered under fed conditions.
4 mg administered under fed conditions
|
OTHER: Cohort 2 Sequence 4 (Part B)
Treatment sequence F, E, H, and G
|
4 mg administered under fasted condition.
4 mg administered under fasted conditions.
4 mg administered under fed conditions.
4 mg administered under fed conditions
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUCinf of 5-HMT
Time Frame: 0 (pre dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 30, 36, and 48 hours
|
Area under the plasma concentration-time curve from time zero extrapolated to infinity.
|
0 (pre dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 30, 36, and 48 hours
|
AUClast of 5-HMT
Time Frame: 0 (pre dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 30, 36, and 48 hours
|
Area under the plasma concentration-time curve from 0 to the time of the last quantifiable concentration.
|
0 (pre dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 30, 36, and 48 hours
|
Cmax of 5-HMT
Time Frame: 0 (pre dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 30, 36, and 48 hours
|
Maximum Observed Plasma Concentration
|
0 (pre dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 30, 36, and 48 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
June 26, 2020
Primary Completion (ACTUAL)
January 4, 2021
Study Completion (ACTUAL)
January 4, 2021
Study Registration Dates
First Submitted
June 26, 2020
First Submitted That Met QC Criteria
June 26, 2020
First Posted (ACTUAL)
July 1, 2020
Study Record Updates
Last Update Posted (ACTUAL)
February 10, 2021
Last Update Submitted That Met QC Criteria
February 8, 2021
Last Verified
February 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urologic Diseases
- Urinary Bladder Diseases
- Lower Urinary Tract Symptoms
- Urological Manifestations
- Nutrition Disorders
- Urinary Bladder, Overactive
- Malnutrition
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Muscarinic Antagonists
- Cholinergic Antagonists
- Cholinergic Agents
- Urological Agents
- Fesoterodine
Other Study ID Numbers
- A0221115
- 2019-001909-24 (EUDRACT_NUMBER)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
Pfizer will provide access to individual de-identified participant data and related study documents (e.g.
protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions.
Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neurogenic Detrusor Overactivity
-
Seoul National University HospitalCompletedNeurogenic Bladder | Detrusor Overactivity | Detrusor UnderactivityKorea, Republic of
-
PfizerCompletedNeurogenic Detrusor OveractivityBelgium
-
PfizerCompletedUrinary Bladder, NeurogenicJapan
-
Astellas Pharma Europe B.V.CompletedNeurogenic Detrusor OveractivityBelgium, Croatia, Turkey, Australia, Denmark, Israel, Jordan, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico, Norway, Philippines, Poland, Romania, Serbia, Slovakia, Taiwan
-
Astellas Pharma Europe B.V.CompletedNeurogenic Detrusor OveractivityUnited States, Belgium, Brazil, Denmark, Hungary, Korea, Republic of, Mexico, Philippines, Poland, Turkey
-
Astellas Pharma IncCompletedOveractive Bladder | Neurogenic Detrusor OveractivityBelgium, Canada, Denmark, Netherlands, Poland, Turkey, United Kingdom
-
Astellas Pharma Europe B.V.CompletedPediatric | Neurogenic Detrusor OveractivityUnited States, Belgium, Korea, Republic of, Philippines, Poland, United Kingdom
-
Novartis PharmaceuticalsTerminatedNeurogenic Urinary Bladder | Neurogenic Bladder Disorder | Neurogenic Dysfunction of the Urinary Bladder | Neurogenic Bladder, Uninhibited | Neurogenic Bladder, SpasticNetherlands, Germany, Switzerland
-
Astellas Pharma Europe B.V.CompletedOveractive Bladder | Neurogenic Detrusor OveractivityDenmark, Poland
-
PfizerCompletedOveractive Bladder | Neurogenic Detrusor OveractivityUnited States
Clinical Trials on Fesoterodine BIC SR4 fasted (Treatment A in Part A, Treatment G in Part B)
-
PfizerCompletedRheumatoid Arthritis | Healthy VolunteersUnited States
-
Kanyos Bio, Inc., a wholly-owned subsidiary of...PfizerRecruitingCeliac DiseaseUnited States, Australia, New Zealand
-
AstraZenecaAcerta Pharma, LLCCompletedBioavailability | B-cell Lymphoid CancerUnited States
-
GangaGen, Inc.CompletedBacterial Infections | Infectious DiseaseSingapore
-
AstraZenecaActive, not recruitingAdvanced Non Small Cell Lung CancerCanada, Poland, Taiwan, United States, Korea, Republic of, Japan, Russian Federation, Ukraine
-
Kazia Therapeutics LimitedCompletedOvarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal NeoplasmsUnited States, Australia
-
Dizal PharmaceuticalsActive, not recruitingBreast Cancer MetastaticChina, United States
-
AstraZenecaCompletedAsthma (Part 1) | COPD (Part 2)United Kingdom
-
Bristol-Myers SquibbRecruiting
-
Tyra Biosciences, IncRecruitingSolid Tumor | Intrahepatic Cholangiocarcinoma | Metastatic Cholangiocarcinoma | Locally Advanced CholangiocarcinomaUnited States